- Home
- Reports Store
- Medical Devices
Molecular Diagnostics Market
Customise your request
Need this report to answer something it does not cover? Tell us the decision you are facing and we will scope the work — or point you to a study that already answers it.
info@cortexmeridian.com+971 56 483 5090Report Scope
| Report ID / SKU | CM-MD-0002 |
|---|---|
| Report Code | CM-MD-P1-1002 |
| Report Type | Market Analysis & Forecast |
| Base Year | 2025 |
| Historical Period | 2021–2025 |
| Forecast Period | 2026–2035 |
| Geographic Scope | Global |
| Global Coverage | Yes |
| Regions Covered | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Countries Covered | US; Canada; Mexico; UK; Germany; France; Italy; Spain; Netherlands; Switzerland; China; India; Japan; South Korea; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa (20 countries) |
| Market Size Unit | USD Billion |
| Volume Unit | Tests / Reagent Kits / Instruments |
| Report Format | PPT / WORD / EXCEL / PDF |
| Page Count | 180-220 |
| Delivery Timeline | 48 hours |
| Sample Available | Yes |
| Author / Analyst | Cortex Meridian Medical Devices Analyst Team |
| Publish Date | October 2026 |
| Last Updated | 2026-10-06 |
Market Overview & Definition

Cortex Meridian Research estimates the global Molecular Diagnostics market at USD 18.8 billion in 2025, expanding to roughly USD 28.1 billion by 2035 at a CAGR of 4.1%. The underlying market mix is changing materially. Pandemic-era respiratory testing created exceptional volumes, but sustainable growth is now shifting toward oncology, inherited disease, transplant testing, antimicrobial resistance, sexually transmitted infections and longitudinal disease monitoring. These applications are smaller in test volume but significantly higher in clinical value and often support repeat testing.
PCR remains the commercial backbone because laboratories already have validated workflows, trained personnel and reimbursement familiarity. However, digital PCR and next-generation sequencing are taking a larger role where sensitivity, quantification or broader genomic profiling justify a higher price point. This creates a two-speed market: established PCR assays support scale and recurring volume, while dPCR and NGS create premium growth pockets in oncology and precision medicine.
Company strategy is reinforcing this transition. Cepheid’s third-generation GeneXpert is designed to protect the installed base while broadening future assay complexity and throughput. Roche’s agreement to acquire SAGA Diagnostics adds molecular residual disease capabilities that combine whole-genome sequencing and digital PCR, extending testing from initial diagnosis into post-treatment surveillance. Its PathAI transaction also strengthens the interface between tissue pathology and molecular biomarkers. The commercial impact is important: as diagnostics moves into recurring disease monitoring, the market gains a more durable revenue profile than one-off infectious-disease testing alone could provide.
Report Description
The Molecular Diagnostics Market covers revenue generated from the defined medical-device products, related consumables and software/services where directly attached to the device workflow. The report excludes unrelated pharmaceuticals and stand-alone healthcare services. The scope is designed for manufacturers, suppliers, distributors, hospitals, diagnostic providers, investors and strategy teams evaluating demand, technology shifts, pricing and competitive opportunity.
Overall Market Dynamics
Drivers
Precision medicine, infectious disease testing, oncology biomarkers, NGS adoption, genetic testing and demand for faster high-sensitivity diagnostics.
Restraints / Risks
Test reimbursement pressure, assay complexity, laboratory skill gaps, changing infectious-disease volumes and regulatory validation requirements.
Opportunities
Digital PCR, oncology panels, antimicrobial resistance, decentralized molecular diagnostics, liquid biopsy and companion diagnostics.
Strategic themes
AI/connectivity, workflow efficiency, reimbursement, regulatory approvals, recurring consumables/service revenue, and regional access expansion.
Segmentation & Scope

By product: reagents, instruments, software/services; by technology: PCR, digital PCR, NGS, ISH, INAAT, microarrays; by application: infectious disease, oncology, genetics, transplant, blood screening; by test location: central lab, point-of-care, self-test; by end user and geography.
Regional & Country Outlook

COUNTRY CHAPTER COVERAGE 1. US: PCR/dPCR/NGS market size; oncology, infectious disease and MRD adoption; FDA approvals; reimbursement; Cepheid/Roche/QIAGEN/Danaher competition. 2. Canada: PCR and oncology testing; provincial reimbursement; centralized molecular labs; NGS adoption; supplier mix. 3. UK: NHS genomics infrastructure; oncology panels; infectious disease PCR; reimbursement; laboratory networks. 4. Germany: molecular lab capacity; oncology and infectious disease testing; reimbursement; PCR/NGS competition. 5. France: oncology biomarkers; national genomic initiatives; infectious disease testing; reimbursement; lab procurement. 6. Italy: PCR installed base; oncology diagnostics; regional lab networks; reimbursement; test menu expansion. 7. Spain: molecular lab demand; oncology and STI testing; procurement; reimbursement; NGS adoption. 8. Netherlands: precision medicine; NGS; liquid biopsy; oncology molecular testing; high-complexity lab adoption. 9. Switzerland: precision oncology; companion diagnostics; pharma ecosystem; NGS/dPCR adoption. 10. China: domestic PCR/NGS vendors; localization; hospital molecular labs; oncology testing; regulatory and pricing environment. 11. India: infectious disease PCR; oncology testing; private diagnostic chains; cost-sensitive platforms; NGS growth. 12. Japan: oncology companion diagnostics; reimbursement; NGS panels; high-complexity labs; local supplier activity. 13. South Korea: precision oncology; NGS; molecular screening; domestic diagnostics companies; reimbursement. 14. Australia: genomics networks; oncology panels; infectious disease testing; reimbursement; central labs. 15. Brazil: PCR demand; oncology testing; reference labs; import pricing; public/private access. 16. Argentina: PCR and oncology molecular testing; import dependence; pricing; lab capacity. 17. Saudi Arabia: genomics investment; oncology diagnostics; molecular lab expansion; localization; tenders. 18. UAE: precision medicine; oncology testing; private lab investment; NGS adoption. 19. South Africa: infectious disease molecular testing; TB/HIV diagnostics; oncology testing; public/private labs.
Competitive Landscape & Companies Covered
Roche; Abbott; QIAGEN; Danaher/Cepheid; Hologic; BD; bioMérieux; Bio-Rad; Thermo Fisher Scientific; Illumina; Sysmex; Seegene
Pricing & Ecosystem
Pricing, Cost & Revenue Intelligence
Pricing intelligence benchmarks capital-system ASPs, disposable/consumable pricing, procedure-linked device pricing, service contracts, software subscriptions and regional tender dynamics where applicable. The model distinguishes capital equipment from recurring revenue and evaluates discounting, bundling, distributor margins, reimbursement sensitivity and premium technology price realization.
Value Chain & Ecosystem Analysis
The ecosystem maps component and sensor suppliers, materials vendors, device OEMs, software/AI partners, contract manufacturers, sterilization and packaging providers, distributors, hospitals/diagnostic laboratories/ASCs, clinicians, payers and regulators. The analysis identifies control points in the value chain, recurring-revenue pools, channel dependencies and partnership opportunities.
Opportunity & White-Space Analysis
A weighted opportunity model scores product segments, technologies, countries, end users and accounts using growth, market size, clinical adoption, reimbursement, competitive intensity, regulatory accessibility and margin potential. Priority white spaces include Digital PCR, oncology panels, antimicrobial resistance, decentralized molecular diagnostics, liquid biopsy and companion diagnostics.
Executive Summary
The Molecular Diagnostics market is estimated at USD 18.8 billion in 2025 and is expected to reach approximately USD 28.1 billion by 2035, representing a CAGR of 4.1%. The main growth engine is no longer exceptional respiratory-test volume; it is the expansion of molecular testing into oncology, MRD, inherited disease and precision medicine, where tests are more clinically differentiated and often repeated over the patient journey.
Cepheid’s next-generation GeneXpert reinforces the value of a large installed PCR platform, while Roche’s proposed SAGA Diagnostics acquisition pushes the market toward higher-value, longitudinal oncology testing. The competitive advantage is increasingly determined by assay menu depth, clinical evidence, automation and the ability to combine molecular results with pathology and broader patient data. This supports steady market expansion even as some infectious-disease categories normalize.
Key Takeaways
- 2025 Cortex normalized estimate: USD 18.8 billion
- 2035 normalized outlook: USD 28.1 billion
- Normalized 2025–2035 CAGR: 4.1%
- Key growth drivers: Precision medicine, infectious disease testing, oncology biomarkers, NGS adoption, genetic testing and demand for faster high-sensitivity diagnostics.
- Priority opportunity areas: Digital PCR, oncology panels, antimicrobial resistance, decentralized molecular diagnostics, liquid biopsy and companion diagnostics.
- Primary competitive set: Roche; Abbott; QIAGEN; Danaher/Cepheid; Hologic; BD; bioMérieux; Bio-Rad; Thermo Fisher Scientific; Illumina; Sysmex; Seegene
Table of Contents
List of Tables
- Global market value, 2021–2035
- Market by product/device type
- Market by technology
- Market by application/procedure
- Market by end user
- Market by region
- Country market sizing
- Installed base/procedure/test indicators
- ASP/pricing benchmark
- Company/product benchmark
- Opportunity attractiveness scoring
List of Figures
- Market size and CAGR outlook
- Segment attractiveness matrix
- Technology adoption curve
- Regional opportunity heat map
- Competitive positioning matrix
- Value-chain ecosystem map
- Pricing/revenue model
- Opportunity prioritization matrix
Research Methodology
Methodology
Cortex Meridian Research applies a triangulated market-sizing framework combining company disclosures, regulatory databases, procedure/test volumes, installed-base indicators, shipment and utilization data, hospital and laboratory purchasing patterns, reimbursement signals, product approvals, and primary research. Public market benchmarks are used only as external calibration points; Cortex values are normalized to the defined scope and forecast period. Forecasts consider technology adoption, procedure/test growth, replacement cycles, pricing, reimbursement, regulatory changes, and regional healthcare investment.
Data Sources & Validation
Company annual reports and investor materials; FDA, EMA and other regulatory databases; WHO and national health agencies; peer-reviewed clinical literature; procurement and reimbursement sources; hospital/laboratory statistics; trade and shipment indicators; company product portfolios; primary interviews; and public market benchmarks used for calibration.
FAQ — Buyer Questions
Q: What is the 2025 global Molecular Diagnostics market size? A: Cortex Meridian Research estimates it at approximately USD 18.8 billion.
Q: What is the 2035 market outlook? A: The normalized outlook is approximately USD 28.1 billion, based on a 4.1% CAGR assumption.
Q: What are the major growth drivers? A: Precision medicine, infectious disease testing, oncology biomarkers, NGS adoption, genetic testing and demand for faster high-sensitivity diagnostics.
Q: Which opportunities should suppliers prioritize? A: Digital PCR, oncology panels, antimicrobial resistance, decentralized molecular diagnostics, liquid biopsy and companion diagnostics.
Customization Options
Customization can include country-level sizing, procedure/test volumes, installed base, ASP benchmarking, hospital/lab account mapping, competitor benchmarking, product pipeline analysis, regulatory and reimbursement tracking, KOL mapping, distributor/channel assessment, and opportunity prioritization.
Need something this report does not cover?
Describe the decision you are facing. If a published study already answers it we will point you there; if not, we will scope the work and come back with timeline and cost.
CM-MD-0002 · CM-MD-P1-1002 · 180-220 pages · Published October 2026 · Cortex Meridian Medical Devices Analyst Team
